<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>) and <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> are <z:hpo ids='HP_0011010'>chronic</z:hpo> and <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002180'>neurodegenerative diseases</z:hpo>, respectively, and <z:hpo ids='HP_0003674'>onsets</z:hpo> of these diseases are thought to be induced at least by <z:mp ids='MP_0003674'>oxidative stress</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> is caused by <z:mp ids='MP_0005643'>decreased dopamine levels</z:mp> in the substantia nigra and striatum, and <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> occurs as a result of local reduction or arrest of blood supply </plain></SENT>
<SENT sid="2" pm="."><plain>Although a precursor of <z:chebi fb="40" ids="18243">dopamine</z:chebi> and inhibitors of <z:chebi fb="40" ids="18243">dopamine</z:chebi> degradation have been used for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> therapy and an anti-oxidant have been used for <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> therapy, cell <z:hpo ids='HP_0011420'>death</z:hpo> progresses during treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Reagents that prevent <z:mp ids='MP_0003674'>oxidative stress</z:mp>-induced cell <z:hpo ids='HP_0011420'>death</z:hpo> are therefore necessary for fundamental therapies for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> and <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>DJ-1, a causative gene product of a familial form of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>, PARK7, plays roles in transcriptional regulation and anti-<z:mp ids='MP_0003674'>oxidative stress</z:mp>, and loss of its function is thought to result in the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Superfluous oxidation of cysteine at amino acid 106 (C106) of DJ-1 renders DJ-1 inactive, and such oxidized DJ-1 has been observed in patients with the <z:hpo ids='HP_0003745'>sporadic</z:hpo> form of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: In this study, a compound, comp-23, that binds to DJ-1 was isolated by virtual screening </plain></SENT>
<SENT sid="7" pm="."><plain>Comp-23 prevented <z:mp ids='MP_0003674'>oxidative stress</z:mp>-induced <z:hpo ids='HP_0011420'>death</z:hpo> of SH-SY5Y cells and primary neuronal cells of the ventral mesencephalon but not that of DJ-1-knockdown SH-SY5Y cells, indicating that the effect of the compound is specific to DJ-1 </plain></SENT>
<SENT sid="8" pm="."><plain>Comp-23 inhibited the production of reactive oxygen species (ROS) induced by <z:mp ids='MP_0003674'>oxidative stress</z:mp> and prevented excess oxidation of DJ-1 </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, comp-23 prevented dopaminergic cell <z:hpo ids='HP_0011420'>death</z:hpo> in the substantia nigra and restored movement abnormality in 6-hydroxyldopamine-injected and <z:chebi fb="0" ids="28201">rotenone</z:chebi>-treated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> model rats and mice </plain></SENT>
<SENT sid="10" pm="."><plain>Comp-23 also reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats that had been induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>Protective activity of comp-23 seemed to be stronger than that of previously identified compound B </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: The results indicate that comp-23 exerts a neuroprotective effect by reducing ROS-mediated neuronal injury, suggesting that comp-23 becomes a lead compound for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> and ischemic <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo> therapies </plain></SENT>
</text></document>